



**For immediate release:  
November 2, 2010**

**For more information, contact:  
Brandi Thompson, 438-7823 x105**

### **Local Retina Specialist Presents Clinical Data at European Conference**

***Pensacola, Fla.*** – Local retina specialist, Dr. Sunil Gupta, recently presented clinical trial results on the use of Ozurdex to the 10<sup>th</sup> EURETINA Congress in Paris in September. EURETINA, the European Society of Retina Specialists is an international non-profit organization that promotes the exchange of knowledge between vitreoretinal and macula specialists in Europe.

Retina Specialty Institute conducted three clinical trials with Ozurdex, a retinal vein occlusion treatment. Ozurdex is a Dexamethasone 0.7mg intravitreal implant that combines a steroid with a binding component of Vicryl suture for slow release of the medication over time.

“Retinal vein occlusions account for the second most common retinal vascular disease,” said Sunil Gupta, M.D. of Retina Specialty Institute. “RVO is a common condition in patients over 40 and, if left untreated, can lead to vision loss. More than 150,000 new cases are diagnosed in the United States each year.”

As a national, randomized, FDA-approved clinical trial study center, Retina Specialty Institute has earned its reputation among major pharmaceutical companies, peers and patients by consistently delivering peak performance. Recent advances, which the institute’s participation in the clinical trials prompted, allow Retina Specialty Institute to further the mission of preserving maximum vision in patients afflicted with retinal disorders. For more information visit [www.retinaspecialty.com](http://www.retinaspecialty.com).

# # #